⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PLX News
Protalix BioTherapeutics, Inc. Common Stock
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
globenewswire.com
PLX
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU
globenewswire.com
PLX
Fishing Net Recycling & Reuse Market Forecast 2025-2030 | Fishing Net Recycling is Transforming Marine Conservation and The Circular Economy
globenewswire.com
PLX
Pluxee Q1 Fiscal 2026 Revenues - Robust start in the 1st quarter delivering on expectations, All Fiscal 2026 financial objectives confirmed
globenewswire.com
PLX
Protalix BioTherapeutics Letter to Stockholders
prnewswire.com
PLX
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
prnewswire.com
PLX
LimeLife Migrates to Ordergroove to Power Scalable, Modern Subscriber Experiences for Global Direct Selling Business
globenewswire.com
ORDR
LRLCF
HLF
PLX
CORRECTION: Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery
globenewswire.com
PLX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
accessnewswire.com
PLX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
accessnewswire.com
PLX